Development and evaluation of recombinant multi-epitopes vaccine against nervous necrosis virus.

Fish Shellfish Immunol

School of Marine Biology and Fisheries, Sanya Institute of Breeding and Multiplication, Collaborative Innovation Center of Marine Science and Technology, Hainan University, China. Electronic address:

Published: July 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Capsid protein (CP) is the antigen of nervous necrosis virus (NNV), a fatal microorganism for almost marine fishes. Antigen epitope is a special chemical group in an antigen molecule that determines the specificity of the antigen, usually consisting of 5-15 amino acid residues. However, the antigen epitope of NNV antigen remains unclear. In this study, using immunoinformatic method, we analyzed the antigen epitope of CP and designed a multi-epitopes vaccine of NNV (PA). Furthermore, we evaluated the immune responses induced by PA vaccine. The results showed that three cytotoxic T lymphocyte epitopes and six B-cell lymphocyte epitopes were predicted, with high antigenicity, non-allergen, and non-toxin. Based on these epitopes, a multi-epitopes vaccine of NNV (PA) was designed and prepared. After immunization, the mRNA expression levels of IL-1β, TNF-α, CD4, CD8, MHC-Ⅰ, and MHC-Ⅱ in PA group were significantly up-regulated. Moreover, it has been proven that PA could significantly activate antigen presenting cells. Importantly, PA could induce similar levels of antibodies secretion and immune protection, compared to CP group. The survival rate reached 77.22 % in PA group. This study provides a cheap and effective strategy for aquatic vaccine design, which will be beneficial in application to development of vaccine in aquaculture industry.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fsi.2025.110332DOI Listing

Publication Analysis

Top Keywords

multi-epitopes vaccine
12
antigen epitope
12
nervous necrosis
8
necrosis virus
8
antigen
8
vaccine nnv
8
lymphocyte epitopes
8
vaccine
6
development evaluation
4
evaluation recombinant
4

Similar Publications

A candidate multi-epitopes vaccine against encephalomyocarditis virus confers protection in mice.

Vet Microbiol

August 2025

Engineering Research Center of Key Technology and Industrialization of Cell-based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China; Gansu Tech Innovation Center of Animal Cell, Biomedical Research Center, Northwest Minzu University, Lanzho

Encephalomyocarditis virus (EMCV) is a widely distributed RNA virus that causes diseases in animals with zoonotic potential. Infection with this pathogen in animals, especially in pigs, can lead to encephalitis, myocarditis, and reproductive disorders. The virus causes a febrile disease in humans and is thus not only a potential threat to the swine industry but also to human health and society.

View Article and Find Full Text PDF

Porcine reproductive and respiratory syndrome virus (PRRSV) is a major viral threat to swine, causing significant economic loss in the global pig farming industry. This virus includes two major genotypes, PRRSV1 and PRRSV2, both characterized by high mutation rates and genetic variability, complicating the development of a universally effective vaccine and disease control. To address this challenge, this study utilizes immunoinformatics tools to identify conserved epitopes and design a multi-epitope vaccine candidate against PRRSV based on reverse vaccinology.

View Article and Find Full Text PDF

Towards precision epitopes based vaccine against by integrating vaccinomics, reverse vaccinology and biophysics approaches.

Biochem Biophys Rep

September 2025

Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, 71491, Saudi Arabia.

is a Gram-positive bacterium and recognized as an etiological agent of different nosocomial infections. has developed resistance to several antibiotics. No licensed vaccine is available to prevent infections.

View Article and Find Full Text PDF

Integrated in-silico design and in vivo validation of multi-epitope vaccines for norovirus.

Virol J

May 2025

Institute of Clinical Science, Clinical Center of Biotherapy, Zhongshan Hospital, Shanghai Institute of Infectious Disease and Biosecurity, Intelligent Medicine Institute, Shanghai Medical College, Fudan University, 200032, Shanghai, China.

Background: Norovirus (NoVs) is a foodborne pathogen that causes acute gastroenteritis. The diversity of its principal antigenic protein poses a significant challenge to vaccine development and the prevention of large-scale outbreaks globally. Currently, no licensed vaccines against norovirus have been approved.

View Article and Find Full Text PDF

Rickettsia is a genus of bacteria that are obligate intracellular parasites and are responsible for the febrile diseases known collectively as Rickettsioses. The emergence of antibiotic resistance is an escalating concern and thus developing a vaccine against Rickettsia is of paramount importance due to the significant public health threat posed by these bacteria. Thus, we employed structural vaccinology guided by machine learning algorithms to explore the virulence landscape of Rickettsia prowazekii to design a multi-epitopes-based vaccine (MEVC) that is immunogenic and safe.

View Article and Find Full Text PDF